1Ozturk MA,Barista I,Imrie K,et al.Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lympho-ma:results of a single-center study of 32 patients.Modified eto-poside,methylprednisolone,cytarabine and cisplatin[J].Chemotherapy,2002,48(5):252-258.
7Rodriguez-Monge EJ,Cabanillas F.Long-term follow-up of platinum-based lymphoma salvage regimens.The MD.Anderson Cancer Center experience[J].Hematol Oncol Clin North Am,1997,11(5):937-947.
8Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rit-uximab compared with CHOP alone in elderly patients with diffuse large-B -cell lymphoma[J].N Engl J Med,2002,346(4):235 -242.
9Feugier P,Van Hoof A,Sebban C,et al.Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Croupe d' Etude des Lym-phomes de l'Adulte[J].J Clin Oncol.,2005,23(18):4 117 -4 126.
5Ozturk M A,Barista I,Imrie K,et al.Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma:results of a single-center study of 32 patients.Modified etoposide,methylprednisolone,cytarabine and cisplatin[J].Chemotherapy,2002,48(5):252-258.
6Girouard C,Dufresne J,Imrie K,et al.Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation[J].Ann Oncol,1997,8(7):675-680.
7Velasquez W S,McLaughlin P,Turker S.ESHAP-an effective chemotherapy regiment in refractory and relapsing lymphoma:a4-year follow-up study[J].Clin Oncol,1997,12 (6):1169-1176.
8Coiffier B,Haioun C,Ketterer N,et al.Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase Ⅱ study[J].Blood,1998,92(6):1927-1932.
9Jermann M,Jost L M,Taverna C H,et al.Rituximab-EPOCH,an effective salvage therapy for relapsed,refractory or transformed B-cell lymphomas:results of a phase Ⅱ study[J].Ann Oncol,2004,15(3):511-516.
10Kewalramani T,Zelenetz A D,Nimer S D,et al.Rituximab and ICE as second-line therapy before autologous stem cell transplantion for relapsed or primary refractory diffuse large Bcell lymphoma[J].Blood,2004,103(10):3684-3688.
2Vose JM,Link BK,Grossbard ML,et al.Phase H study of ritux-imab in combination with chop chemotherapy in patients with previ-ously untreated,aggressive non-hodgkin's lymphoma [J].J Clin On-col,2001,19(2):389-397.
3Aksoy S,Dizdar O,Hayran M,et al.Infectious complications ofrituximab in patients with lymphoma during maintenance therapy:asystematic review and meta-analysis [J].Leuk Lymphoma,2009,50(3):357-365.
5Nishio M,Fujimoto K,Yamamoto S,et al.Hypogammaglobu-linemia with a selective delayed recovery in memory B cells andan.impaired isotype expression after rituximab administiation asan adjuvant to autologous stem cell transplantation for non-hodg-kin lymphoma [J].Eur J Haematol,2006,77(3):226-232.
6Cooper N,Davies EG,Thrasher AJ.Repeated courses of rituximabfor autoimmune cytopenias may precipitate profound hypogamma-globulinaemia requiring replacement intravenous immunoglobulin[J].Br J Haematol,2009,146(1):120-122.
7Fukushima N,Mizuta T,Tanaka M,et al.Retrospective and pro-spective studies of hepatitis B vims reactivationin malignant lym-phoma with occult HBV carrier [J].Ann Oncol,2009,20(12):2013-2017.
8Aksoy S,Abali H,Kilickap S,et al.Accelerated hepatitis C virusreplication with rituximab treatment in a non-hodgkin's lymphomapatient [J].Clin Lab Haematol,2006,28(3):211-214.
9Oliver C, Guillermo C, Martinez P, et al. Comparison be- tween CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma[J]. 2013,141(7):844-852.
10Rauh R, Kahl S, Boechzelt H, et al. Molecular biology of cantharidinin cancer cells[J]. Chin Med, 2007,4 (2) : 8.
